the question for czd/polynovo

This is a paragraph from a release by Arteriocyte a company that has recently received a BARDA contract valued in stages of $101+mUS.

It seems to me that Polynovo and Dr Greenwood are about solving the problem posed in the paragraph.

If this could be conveyed to the investing public along with the progress to achieving the answer there might be some appetite for cZD shares!!

http://arteriocyte.com/

Thermal Wound Treatments
Treatment of severe burns is a rapidly emerging segment of advanced wound care. Each year, in the United States, approximately 1.1 million burn injuries require some level of medical attention. Approximately 50,000 require significant surgical intervention including debridement of damaged/dead tissue, creating a bleeding wound bed, and application of patient harvested or donor skin grafts. Second- and third-degree burn wounds require specialized medical/surgical care and time to heal due to the heat induced damage to the skin and the vessels that feed the tissue in the area surrounding the wound, often resulting in necrosis rather than healing. To date, no single therapy has shown an ability to supply immediate wound protection and healing, provide a bridge to delayed definitive care, and improve graft integration simultaneously. Most therapies focus on one aspect of the thermal wound tissue regeneration and require other therapies to be fully effective. Current literature suggests that growth-factor rich platelet rich plasma (PRP) plays a role in stimulating new blood vessel growth and recruiting keratinocytes to re-epithelialize wounds while decreasing pain and risk of infection.

My position is still buy and I bought the lions share today.